Drug makers question idea to shake up how Medicare pays for certain drugs

first_img WASHINGTON — Drug manufacturers are pushing back against one of the administration’s major proposals to bring down drug prices: a proposal to shift chemotherapy drugs and others administered in the hospital into a different part of Medicare.The idea — which Health and Human Services Secretary Alex Azar first hinted at in his confirmation hearings and then proposed in the Trump administration’s fiscal year 2019 budget — would give insurance companies and pharmacy benefit managers new power to negotiate discounts on some of Medicare’s costliest drugs. That could mean big savings for the Medicare program itself, which might be passed on to consumers. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Health and Human Services Secretary Alex Azar Chris Kleponis/Getty Images Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. First 30 days free. GET STARTED What’s included? Politics About the Authors Reprints Erin Mershon Senior News Editor Log In | Learn More center_img Drug makers question idea to shake up how Medicare pays for certain drugs What is it? By Erin Mershon and Ike Swetlitz April 24, 2018 Reprints [email protected] @eemershon GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Tags Donald Trumpdrug pricingMedicarepharmaceuticalspolicySTAT+last_img read more